Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OKI-179 + binimetinib · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| OKI-179 + binimetinib | DRUG | Phase 1b: With a 3+3 dose escalation design, enrollment in Phase 1b will proceed until the MTD has been defined or the highest dose level has been reached. OKI-179 will be administered on a 4-days-on/3-days-off schedule, while binimetinib will be administered BID continuously. Phase 2: Patients will be treated with the RP2D. |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Tango Therapeutics, Inc. | TNGX | 1 | PHASE1 | TNG462, RMC-9805, RMC-6236, mFOLFIRINOX, gemcitabine/nab-paclitaxel |
| Pasithea Therapeutics Corp. | KTTA | 1 | PHASE1 | PAS-004 |
| Adlai Nortye Ltd. Sponsored ADR | ANL | 1 | PHASE1 | AN9025 |
| Myriad Genetics, Inc. | MYGN | 1 | PHASE1 | Melphalan, BCNU, Vitamin B12B, Vitamin C |
OKI-179 is an investigational small molecule being studied for the treatment of advanced solid tumors and cancers with RAS pathway mutations, including NRAS-mutated melanoma. It is currently in clinical development and has not been approved by the FDA.
OKI-179 is a small molecule that targets the RAS pathway, which is involved in cell growth and division. It is being studied in patients with RAS mutations, including NRAS gene mutations, to potentially treat advanced solid tumors and melanoma.
OKI-179 is being developed by OnKure Therapeutics, Inc., a biopharmaceutical company. OnKure is publicly traded on the NASDAQ under the ticker symbol OKUR.
OKI-179 is in Phase 1 clinical development. It has completed a Phase 1 trial and a Phase 1/2 trial, but it is still investigational and has not been approved by the FDA.
OKI-179 has been studied in two clinical trials. The first, NCT03931681, was a Phase 1 study in patients with advanced solid tumors. The second, NCT05340621, was a Phase 1/2 study called NAUTILUS, which evaluated OKI-179 plus binimetinib in patients with advanced solid tumors in the RAS pathway and NRAS-mutated melanoma.
OKI-179 is also known by its code name OKI-179. It is sometimes referred to as OKI-179 in clinical trial records. No other alternative names have been reported.